DGI:Opportunistische Infektionen/CMV/Quellen

• Robert Koch-Institut. RKI-Ratgeber Zytomegalievirus-Infektion. Stand 24.10.2023.
• Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102(6):900–931.
• Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients – Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13512.
• Limaye AP, Budde K, Humar A, et al. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA. 2023;330(1):33–42.
• Marty FM, Ljungman P, Chemaly RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017;377(25):2433–2444.
• Avery RK, Alain S, Alexander BD, et al. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial (SOLSTICE). Clin Infect Dis. 2022;75(4):690–701.
• Papanicolaou GA, Avery RK, Cordonnier C, et al. Maribavir versus Valganciclovir for First CMV Infection Post-Hematopoietic Cell Transplant (AURORA). Clin Infect Dis. 2024;78(3):562–572.
• Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation (ECIL-7). Lancet Infect Dis. 2019;19(8):e260–e272.
• Fryer JF, Heath AB, Minor P, et al. A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology. Biologicals. 2016;44(4):242–251.